Our news Archives
Phase II Grant to develop a Donor Specific Antibody (DSA) diagnostic microassay with greater specificity and accuracy for acute and chronic antibody mediated rejection (AMR) of organ transplants
Dr. Mayer will lead PTS's clinical research strategies and support ongoing business development.
ImmunoCellular Therapeutics Establishes Agreement with Pure MHC for Novel Quality Control Assay for ICT-107 Phase 3 Registrational Trial
PureMHC and PhosImmune Working Together On Immunotherapies for Cancer
The grant will support the development of a multi-analyte assay device to detect the adverse immunological response against either donor or recipient-derived HLA that often occurs in transplant patients.